DK1393277T3 - Anvendelse af NF-Kappa-B inhibitorer til behandling af öjentörhedslidelser - Google Patents

Anvendelse af NF-Kappa-B inhibitorer til behandling af öjentörhedslidelser

Info

Publication number
DK1393277T3
DK1393277T3 DK02736994T DK02736994T DK1393277T3 DK 1393277 T3 DK1393277 T3 DK 1393277T3 DK 02736994 T DK02736994 T DK 02736994T DK 02736994 T DK02736994 T DK 02736994T DK 1393277 T3 DK1393277 T3 DK 1393277T3
Authority
DK
Denmark
Prior art keywords
inhibitors
kappa
eye disorders
treat eye
disorders
Prior art date
Application number
DK02736994T
Other languages
Danish (da)
English (en)
Inventor
Daniel A Gamache
John M Yanni
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of DK1393277T3 publication Critical patent/DK1393277T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK02736994T 2001-05-21 2002-05-17 Anvendelse af NF-Kappa-B inhibitorer til behandling af öjentörhedslidelser DK1393277T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29249501P 2001-05-21 2001-05-21

Publications (1)

Publication Number Publication Date
DK1393277T3 true DK1393277T3 (da) 2006-10-30

Family

ID=23124921

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02736994T DK1393277T3 (da) 2001-05-21 2002-05-17 Anvendelse af NF-Kappa-B inhibitorer til behandling af öjentörhedslidelser

Country Status (17)

Country Link
US (1) US6696453B2 (de)
EP (1) EP1393277B1 (de)
JP (1) JP2004527578A (de)
CN (1) CN1509462A (de)
AT (1) ATE333273T1 (de)
AU (1) AU2002309963B2 (de)
BR (1) BR0209965A (de)
CA (1) CA2447883A1 (de)
CY (1) CY1105220T1 (de)
DE (1) DE60213230T2 (de)
DK (1) DK1393277T3 (de)
ES (1) ES2263785T3 (de)
MX (1) MXPA03010632A (de)
PL (1) PL367286A1 (de)
PT (1) PT1393277E (de)
WO (1) WO2002095704A1 (de)
ZA (1) ZA200308769B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374700A1 (en) * 2002-09-20 2005-10-31 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US4744980A (en) 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US4996209A (en) 1988-06-20 1991-02-26 Alcon Laboratories, Inc. Ophthalmic antiinflammatory compositions comprising S(+)-flurbiprofen
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5583150A (en) 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ATE132366T1 (de) 1990-05-29 1996-01-15 Boston Ocular Res Zusammensetzung zur behandlung von dry eye erkrankungen
DE4028906A1 (de) 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
DE4140184C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
AU674681B2 (en) 1992-04-21 1997-01-09 Schepens Eye Research Institute, Inc., The Ocular androgen therapy in Sjogren's syndrome
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5686436A (en) 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
FR2718441B1 (fr) 1994-04-07 1996-06-28 Bioxytech Nouveaux composés de structure benzisoséléna-zoline et -zine, leur procédé de préparation et leurs applications thérapeutiques.
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
AU715430B2 (en) 1995-08-14 2000-02-03 Optigenex, Inc. Carotenoid-nicotinamide-zinc compositions and methods of treatment using same
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6100299A (en) 1996-03-08 2000-08-08 Oxigene, Inc. N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
US6028111A (en) 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
US6046185A (en) 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6207458B1 (en) 1998-05-07 2001-03-27 University Of Washigton/Stowers Insitute For Medical Research Proteins capable of regulating NF-κB JNK and apoptosis pathways and methods of using the same
KR100598723B1 (ko) 1998-07-14 2006-07-11 알콘 매뉴팩츄어링, 리미티드 비알레르기성 안염증 질환 치료 및 안혈관신생 예방용약제를 제조하기 위한11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[β,ε]옥세핀-2-아세트산의 용도
WO2000043000A1 (fr) 1999-01-20 2000-07-27 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de proteasome
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
EP1173413B1 (de) 1999-04-27 2004-06-30 Novartis AG 2,4-diamino-3-hydroxycarboxylsäurederivate als proteasome inhibitoren

Also Published As

Publication number Publication date
AU2002309963B2 (en) 2007-03-01
CY1105220T1 (el) 2010-03-03
ES2263785T3 (es) 2006-12-16
WO2002095704A8 (en) 2003-09-18
CA2447883A1 (en) 2002-11-28
JP2004527578A (ja) 2004-09-09
MXPA03010632A (es) 2004-03-09
PL367286A1 (en) 2005-02-21
PT1393277E (pt) 2006-09-29
WO2002095704A1 (en) 2002-11-28
DE60213230T2 (de) 2006-11-23
CN1509462A (zh) 2004-06-30
US6696453B2 (en) 2004-02-24
EP1393277B1 (de) 2006-07-19
WO2002095704A9 (en) 2003-02-27
DE60213230D1 (de) 2006-08-31
EP1393277A1 (de) 2004-03-03
ZA200308769B (en) 2005-01-26
ATE333273T1 (de) 2006-08-15
US20030008854A1 (en) 2003-01-09
BR0209965A (pt) 2004-04-06

Similar Documents

Publication Publication Date Title
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
AU2002305756A8 (en) Use of nf-kappa-b inhibitors to treat dry eye disorders
DK1459750T3 (da) (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DK3167872T3 (da) Fremgangsmåder til behandling af inflammationsmedierede tilstande i øjet
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
DK1754707T3 (da) Multicykliske forbindelser og anvendelse deraf som inhibitorer af PARP-, VEGFR2- og MLK3-enzymer
ATE340844T1 (de) Stabile, wässerige zusammensetzungen zur behandlung von oberflächen , insbesondere geweben
DE60101265D1 (de) Behandlung von augenschmerzen
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
TR200401862T4 (tr) Tolerans ve bağımlılığı tedavi etmek için metabotropik glutamat reseptör antagonistleri.
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
DE60101559D1 (de) Benutzung von comt-inhibitoren als analgetika
DK1744736T3 (da) Fremgangsmåde til behandling af problemer med tørre øjne og uveitis
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
EA200401032A1 (ru) Антиинфарктные молекулы
DK1393277T3 (da) Anvendelse af NF-Kappa-B inhibitorer til behandling af öjentörhedslidelser
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
DK1150682T3 (da) Ubichinon Qn til behandling af migrænesmerter
DK1500395T3 (da) Reboxetin til behandling af fibromyalgi og andre somatoforme lidelser
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
SE0003126D0 (sv) Method of treatment
TR200101476T2 (tr) N-ikameli azabisikloaklan türevlerinin merkezi sinir sistemi bozukluklarının tedavisinde kullanılması